Welcome to our dedicated page for DAXOR SEC filings (Ticker: DXR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Daxor Corporation filings document material events, capital-structure activity, governance votes, and regulatory disclosures for a Nasdaq-listed medical instrumentation and biotechnology company focused on blood volume measurement. Recent 8-K filings describe registered common-stock offerings, securities purchase and placement agency agreements, investor presentation materials, and the company’s common stock registration on Nasdaq.
The filing record also includes disclosures tied to FDA clearance for Daxor’s rapid, portable lab-based Blood Volume Analysis system, as well as annual meeting results covering director elections and auditor ratification. These documents frame the company’s formal reporting around BVA commercialization, financing, shareholder governance, and public-company compliance.
DAXOR CORP (symbol: DXR) is the issuer of record for a Form 4 filing submitted to the SEC.
DAXOR CORP (DXR) reports unaudited results for the six months ended June 30, 2026, showing net assets of $51.8 million, up from $45.9 million at December 31, 2025, primarily from a January 2026 registered direct equity offering of $9.0 million (765,958 shares at $11.75).
Net asset value per share was $8.88 versus $9.07 at year-end, as operating and investment losses of $3.31 million more than offset offering accretion and stock-based compensation. DXR’s balance sheet is debt-free, with $5.8 million in U.S. Treasury bills and a Level 3 fair value of $46.0 million assigned to its medical operating division. Equity awards outstanding (options plus unvested stock) equal about 4.5% of shares outstanding.
Management highlights 16% kit sales growth in the first half of 2026, manufacturing and inventory investments funded from offering proceeds, and retirement of a $1.17 million CEO loan to the operating division. DXR continues seeking SEC approval to cease being a registered investment company and fully align reporting with its diagnostics and radiopharmaceutical business, while expanding its Blood Volume Analysis platform and adding new IP such as U.S. Patent No. 12,635,917 B2.
Daxor Corp reported that its Chief Financial Officer, Michel Robert J, received a compensation-related stock grant. He was awarded 12,000 shares of Daxor Common Stock at no purchase price, which are scheduled to vest on June 23, 2026. Following this grant, he directly holds 33,050 shares of the company’s common stock. This is a non-market transaction classified as a grant or award acquisition rather than an open-market share purchase.
Feldschuh Michael Richard reported acquisition or exercise transactions in this Form 4 filing.
DAXOR CORP Chief Executive Officer Michael Richard Feldschuh reported receiving a grant of 30,000 shares of Daxor Common Stock. The award was recorded at a price of $0.00 per share and is compensation-related rather than an open-market purchase. According to a footnote, the 30,000 granted shares vest on June 23, 2026. After this grant, Feldschuh directly holds a total of 243,694 shares of Daxor Common Stock.
Feldschuh Jonathan Adam reported acquisition or exercise transactions in this Form 4 filing.
DAXOR CORP Chief Scientific Officer Jonathan Adam Feldschuh received an equity grant of 25,000 shares of Daxor common stock. The shares were granted at a price of $0.00 per share as a stock award rather than an open-market purchase.
According to the filing, Feldschuh now holds a total of 78,908 Daxor common shares directly after this award. A footnote states that the 25,000 granted shares vest on June 23, 2026, meaning they become fully earned on that date if applicable conditions are met.
Daxor Corp director Joy S. Goudie reported receiving a grant of 2,500 stock options to buy common stock at an exercise price of $10.14 per share. The options expire on June 23, 2031 and are scheduled to vest in three annual installments from June 23, 2026 through June 23, 2028. The grant is contingent on SEC approval of an amendment to the Daxor Corporation 2020 Incentive Compensation Plan.
Daxor Corp director Henry D. Cremisi received a grant of stock options for 2,500 shares of common stock. The options carry an exercise price of $10.14 per share and expire on June 23, 2031. This is a compensation-related award, not an open-market trade.
The grant is contingent on SEC approval of an amendment to the Daxor Corporation 2020 Incentive Compensation Plan. The options are scheduled to vest in three installments: 833 options on June 23, 2026, 883 on June 23, 2027, and 834 on June 23, 2028.
DAXOR CORP director Edward Feuer received a grant of 2,500 stock options as compensation. These options give him the right to buy common stock at an exercise price of $10.14 per share and expire on June 23, 2031.
The grant is contingent on approval by the Securities & Exchange Commission to amend the Daxor Corporation 2020 Incentive Compensation Plan. The options are scheduled to vest in three annual installments: 833 options on June 23, 2026, 833 on June 23, 2027, and 834 on June 23, 2028. After this grant, Feuer holds 2,500 stock options directly.
DAXOR CORP reported that director-level insider Caleb DesRosiers received a grant of stock options for 2,500 shares of common stock at an exercise price of $10.14 per share. These options are contingent on SEC approval of an amendment to the Daxor Corporation 2020 Incentive Compensation Plan and will vest in three annual installments through June 23, 2028.
Daxor Corporation held its Annual Meeting on June 23, 2026, where shareholders elected six directors for terms ending at the 2027 annual meeting. Henry D. Cremisi, Edward Feuer, Joy Goudie, Michael Feldschuh, Jonathan Feldschuh, and Caleb DesRosiers each received strong majority support, with individual "for" votes ranging from about 4.1 million to 4.4 million shares.
Shareholders also approved the ratification of Bush & Associates, CPA as Daxor’s independent registered public accounting firm, with 4,423,295 votes for, 19,839 against, and 401 abstentions. The filing reiterates that Daxor, listed on Nasdaq as DXR, is a medical instrumentation and biotechnology company focused on its FDA-cleared BVA-100 blood volume analyzer.